Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 5,145,600 | 5,872,200 | 4,860,400 | 4,103,728 | 2,819,557 |
| Cost of Goods | 417,500 | 397,100 | 299,700 | 392,709 | 205,018 |
| Gross Profit | 4,728,100 | 5,475,100 | 4,560,700 | 3,711,019 | 2,614,539 |
| Operating Expenses | 2,194,200 | 3,395,600 | 3,230,700 | 2,459,812 | 1,790,638 |
| Operating Income | 2,534,400 | 2,079,600 | 1,330,700 | 1,251,916 | 823,919 |
| Interest Expense | 28,200 | 25,100 | 7,200 | 14,241 | 37,372 |
| Other Income | 47,300 | 24,000 | 6,300 | -12,578 | -25,312 |
| Pre-tax Income | 2,553,500 | 2,078,500 | 1,329,800 | 1,225,097 | 761,235 |
| Income Tax | 109,100 | 880,000 | 434,300 | 589,041 | 423,109 |
| Net Income Continuous | 2,444,400 | 1,198,500 | 895,500 | 636,056 | 338,126 |
| Net Income | $2,444,400 | $1,198,500 | $895,500 | $636,056 | $338,126 |
| EPS Basic Total Ops | 22.65 | 11.27 | 8.55 | 6.17 | 3.36 |
| EPS Basic Continuous Ops | 22.65 | 11.27 | 8.55 | 6.17 | 3.36 |
| EPS Diluted Total Ops | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 |
| EPS Diluted Continuous Ops | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 |
| EPS Diluted Before Non-Recurring Items | 19.80 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $2,682,600 | $2,225,100 | $1,435,400 | $1,326,825 | $876,605 |